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A Glycosylphosphatidylinositol-Based Treatment Alleviates
Trypanosomiasis-Associated Immunopathology1
Benoît Stijlemans,2* Toya Nath Baral,* Martin Guilliams,* Lea Brys,* Johanna Korf,†
Michael Drennan,* Jan Van Den Abbeele,‡ Patrick De Baetselier,* and Stefan Magez*
The GPI-anchored trypanosome variant surface glycoprotein (VSG) triggers macrophages to produce TNF, involved in trypano-
somiasis-associated inflammation and the clinical manifestation of sleeping sickness. Aiming at inhibiting immunopathology dur-
ing experimental Trypanosoma brucei infections, a VSG-derived GPI-based treatment approach was developed. To achieve this,
mice were exposed to the GPI before an infectious trypanosome challenge. This GPI-based strategy resulted in a significant
prolonged survival and a substantial protection against infection-associated weight loss, liver damage, acidosis, and anemia; the
latter was shown to be Ab-independent and correlated with reduced macrophage-mediated RBC clearance. In addition, GPI-based
treatment resulted in reduced circulating serum levels of the inflammatory cytokines TNF and IL-6, abrogation of infection-
induced LPS hypersensitivity, and an increase in circulating IL-10. At the level of trypanosomiasis-associated macrophage acti-
vation, the GPI-based treatment resulted in an impaired secretion of TNF by VSG and LPS pulsed macrophages, a reduced
expression of the inflammatory cytokine genes TNF, IL-6, and IL-12, and an increased expression of the anti-inflammatory
cytokine gene IL-10. In addition, this change in cytokine pattern upon GPI-based treatment was associated with the expression
of alternatively activated macrophage markers. Finally, the GPI-based treatment also reduced the infection-associated pathology
in Trypanosoma congolense and Trypanosoma evansi model systems as well as in tsetse fly challenge experiments, indicating
potential field applicability for this intervention strategy. The Journal of Immunology, 2007, 179: 4003–4014.
T rypanosomiasis is a lethal disease affecting both humansand livestock. Although human African trypanosomiasisor sleeping sickness is caused by Trypanosoma brucei
rhodesiense and Trypanosoma brucei gambiense, animal trypano-
somiasis is caused by Trypanosoma congolense, Trypanosoma
vivax, T. brucei brucei and Trypanosoma evansi (1, 2). Conven-
tional anti-trypanosome treatment of infected hosts faces several
problems including high drug toxicity and increasing drug resis-
tance (2–4). In addition, the wide distribution of trypanosomes
throughout the African wildlife reservoir confronts the region with
an extensive problem of reinfection (5). Although vaccination
against trypanosomes offers the most sustainable long-term solu-
tion, so far this strategy is beyond reach. Indeed trypanosomes are
extracellular parasites that are adapted to immune confrontation
through a mechanism of antigenic variation of GPI-anchored vari-
ant surface glycoproteins (VSG)3 (6, 7). During infection, released
VSG interacts with various immune cells triggering an effective
host anti-parasite immune response, including macrophage and B
cell activation and Th1 cell stimulation (8, 9). Although this re-
sponse efficiently eliminates trypanosomes expressing the target
VSG, VSG switching allows immune escape and development of
a new parasitemia wave. Consequently the immune system is
chronically exposed to damaged trypanosomes and thereof re-
leased components that may elicit infection-associated immuno-
pathology. Hereby, massive release of VSG-associated GPI moi-
eties could play a major role. Indeed we, and others, have shown
that the GPI moiety of VSG triggers macrophages to release proin-
flammatory cytokines in particular TNF (10–12). Though the
proinflammatory potential of GPI molecules was amply docu-
mented in different parasitic infections including Chagas’ disease
(13), leishmaniasis (14), trypanosomiasis (15), and malaria (16), so
far compelling evidence for a relationship between the proinflam-
matory properties and disease-inducing potential of parasite-de-
rived GPIs was provided only for malaria. In the first instance,
adults who acquired resistance to clinical malaria manifested per-
sistently increased levels of serum anti-GPI Abs, whereas suscep-
tible patients that suffered from malaria-associated anemia and fe-
ver, lacked an anti-GPI Ab response (17, 18) suggesting a
protective role of anti-GPI Abs against clinical malaria. Second, a
GPI carbohydrate core-based vaccine that conferred partial pro-
tection to malaria-associated pathology was designed (19). In view
of these findings and based on the documented role of the GPI
moiety of VSG in trypanosomiasis-associated pathology (12), an
anti-trypanosome GPI intervention strategy was envisaged to pro-
tect against sleeping sickness. However, during trypanosomiasis, it
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should be emphasized that both the lipid (dimeristoylglycerol com-
pound: DMG) and carbohydrate moiety of the GPI play distinct
roles in macrophage activation and TNF-mediated immunopathol-
ogy (20). Although the galactose-modified glycosylinositol phos-
phate moiety (GIP) of VSG is the minimal moiety needed for the
optimal induction of TNF production by IFN- activated macro-
phages, the DMG compound contributes to macrophage overacti-
vation (TNF and IL-1 secretion) and LPS hypersensitivity during
chronic trypanosome infections (12). Thus in the present work,
animals were treated with intact GPI (encompassing both the lipid
and the carbohydrate moiety) before infection with trypanosomes.
Upon subsequent trypanosome challenge, the GPI-based treatment
was found to 1) alleviate infection-associated inflammation and
pathology, 2) prolong the host survival, and 3) modulate the mac-
rophage activation state. Interestingly, in contrast to what could be
expected based upon the malaria GPI vaccination studies, the pro-
tective effect of GPI-based treatment on pathology is B cell inde-
pendent, and probably mediated by the alteration of the macro-
phage activation stage.
Materials and Methods
VSG purification
Trypanosoma brucei brucei AnTat 1.1, T. congolense Tc13 and T. evansi
(ITMAS 110297, code KETRI 2480) were used to isolate VSG. Soluble
VSG (sVSG) was obtained as described by Stijlemans et al. (21) and an-
alyzed in SDS-PAGE for purity (95%). Membrane form VSG (mfVSG)
was obtained through a combination of previously described protocols (22,
23), followed by an additional gel filtration step. In short, 3  109 parasites
were resuspended in (8 ml each) ice-cold PBS and protease inhibitor so-
lution (2 mM N--p-tosyl-L-lysine chloromethyl ketone (TLCK), 1 tablet
of complete protease inhibitor (Roche) supplemented with 20 mM p-chlo-
romercurybenzenesulfonic acid (PCMBS; Sigma-Aldrich) as inhibitor of
the PLC, and incubated for 30 min on ice followed by a three times alter-
ation from liquid nitrogen/37°C. Parasites were pelleted and resuspended
in solution A (100 mM HEPES NaOH (pH 6.9) 10 mM PCMBS, 1 mM
TLCK, 0.1 mM PMSF). The soluble part was removed by ultracentrifu-
gation (Centrikon T-2070; BRS Belgium) (100,000 g for 30 min at 4°C),
and the pellet was resuspended in solution A containing 2% n-octylgluco-
pyranoside (Roche) for 15 min on ice. Following a final ultracentrifugation
step (100,000  g for 60 min at 4°C), resulting mfVSG was concentrated,
passed over a size-exclusion column (Superdex 75; Pharmacia) equili-
brated against 10 mM Tris, 0.05% n-octylglucopyranoside (pH 7.5) and
checked in SDS-PAGE for purity (95%). Western blot analysis, using
rabbit polyclonal anti-VSG and anti-cross-reacting determinant Abs con-
firmed the presence of the GPI anchor on mfVSG (24).
HPLC purification of the GPI moiety
A modification of the method described by Ferguson et al. (25) was used
to isolate the GPI moiety. In brief, purified mfVSG (1–5 mg) was supple-
mented with 1 mM CaCl2 before digestion with 2% by weight of Pronase
(Roche) for 12 h at 37°C, followed by an additional 12 h digestion with
0.2% Pronase. The released GPI was extracted with water-saturated 1-bu-
tanol, washed with water, dried, and further separated from contaminating
peptides by reverse-phase chromatography using a C2/C18 column (Phar-
macia) equilibrated with 0.1% trifluoroacetic acid. Fractions collected by
applying a linear gradient of 10–60% isopropanol containing 0.1% triflu-
oroacetic acid were lyophilized and resolved in water-saturated 1-butanol.
Identification of the GPI-containing fraction was achieved by a combina-
tion of thin-layer chromatography (Polygram Sil-60; Macherey Nagel)
combined with Orcinol (Sigma-Aldrich) staining and a phosphate detection
assay (phosphorous determination kit; Sigma-Aldrich). Fractions that
stained positive in both tests were pooled and confirmed to be the GPI
moiety by positive-ion MALDI-TOF. This sample was confirmed by the
Limulus amebocyte lysate assay (LAL assay; Biowhittaker) to be LPS free.
Preparation of liposomes containing GPI
The method of Bangham et al. (26) for the preparation of liposomes was
followed. In brief, 1–5 g of purified GPI, determined according to a
phosphorus determination kit, was lyophilized and mixed with 45 l of
phosphatidylcholine (Sigma-Aldrich; 100 g/ml in chloroform) in 1.5 ml
of Eppendorfs. Chloroform was evaporated under a stream of N2-gas, and
1 ml of sterile PBS was added. The suspension was processed in an ultra-
sound bath at 60°C for 20 min, followed by a vortex step (10 min). Non-
incorporated material was removed by washing three times with PBS. The
obtained GPI liposomes were resuspended in 1 ml of PBS. Control lipo-
some suspensions were prepared similarly without the addition of GPI.
Immunization
Groups of 5–10 male C57BL/6 or BALB/c, 8-wk-old mice (Harlan) or B
cell-deficient and CD1d-deficient mice (a gift from Dr. B. Ryffel, CNRS,
France) or C3H/HeN, TLR4/ and TLR2/4/ mice (obtained from Tu-
larik) were used. Taking into account that the GPI moiety lacks conven-
tional T cell epitopes (27), 8-mercaptoguanosine (8-MG) (Sigma-Aldrich)
was used to increase immune responses against GPI liposomes. This bio-
logical response modifier triggers T cell independent B cell activation,
including Ab isotype class switch to IgG (28, 29). 1) GPI-based pre-ex-
posure: mice were injected i.p. with 200 l of 8-MG (30 mg/ml) 2 h before
the injection of 100 l GPI liposomes (corresponding to 0.1–0.5 g GPI).
Three weeks later mice were again injected with 8-MG and GPI liposome
boosted. 2) Mock-treated mice were treated as above with empty lipo-
somes. As additional groups of mice, 8-MG treatment was omitted before
injection of empty liposomes or GPI liposomes. Mice were bled 2 wk later
and sera were tested for their anti-GPI Ab titer on both mfVSG and
purified GPI.
Experimental infections
Clonal infections were performed by using frozen stabilate stocks of An-
Tat1.1, Tc13, or KETRI2480 parasites. Mice were infected by i.p. injection
with 5  103 trypanosomes (diluted in PBS) per mouse, 3 wk after the
boost.
Tsetse fly transmitted trypanosome infections were performed at the same
time point after the boost. In brief, freshly emerged tsetse flies were infected
by feeding on AnTAR1 infected mice at the peak of parasitemie. To obtain a
pleomorphic trypanosome population at high titer, these mice were immune
suppressed with cyclophosphamide (20 mg/kg; Sigma-Aldrich). Flies were
screened for a mature salivary gland infection 28 days after the infected
bloodmeal by induced probing on prewarmed glass slides followed by a
microscopic analysis for the presence of metacyclic trypanosomes in the
saliva. Infection of tsetse flies with T. brucei parasites was performed in
compliance with the regulations for bio-safety and under approval from the
Environmental administration of the Flemish government. To initiate a
natural infection, one individual tsetse fly with a mature salivary gland
infection was allowed to feed per mouse. To avoid interrupted tsetse feed-
ing, mice were anesthetized before the tsetse exposure.
Solid-phase binding ELISA
Purified VSGs (AnTat 1.1, Tc13, or KETRI 2480) were coated onto 96-
wells plates (Nunc) (100 l of 1 g/ml in 0.1 M NaHCO3 (pH 8.2)). After
blocking (2 h, room temperature, 10% FCS in PBS) plates were incubated
with serial dilutions of serum and bound IgG were detected with an anti-
mouse-HRP Ab (Sigma-Aldrich) using peroxidase substrate. Plates were
washed three times in between each step with PBS/0.1% Tween 20. De-
tection of anti-GPI Abs was also performed on purified GPI coated on
96-well Immunolon-2HB plates (Thermo Labsystems) as described for
VSG-coated plates with the exception that washings and Ab dilutions were
performed in PBS without Tween 20.
Cytokine and RBC analysis
Concentrations of TNF (R&D Systems), IL-6, and IL-10 (Pharmingen) in
serum and cell supernatants were determined by sandwich ELISA as rec-
ommended by the suppliers.
RBC counts in blood taken by tail-cut were performed via
hematocytometer.
Serum pH and aspartate transaminase level measurement
Serum pH levels were measured using the UriCheck-9 test (RapiMed Di-
agnostics) according to the manufacturers’ instructions. Serum levels of
AST, as indicator of hepatocellular damage, were determined by an AST/
GOT kit (Sigma-Aldrich).
Locomotor activity measurement
This was measured as the total time per hour spent by mice on running in
their cage, eating, drinking, and cleaning their fur and nest. Mice were kept
in a 12-h light/dark regimen, and locomotor activity was recorded during
the first 2 h of the light period, 8 days postinfection (p.i.).
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Cell cultures
Peritoneal cells from GPI-based treated or mock-treated infected mice (10
days p.i.) were cultured in 48-well plates (Nunc; 5  105 cells/ml) in
complete RPMI 1640 supplemented with 2 mM glutamine, 1 mM pyruvate,
50 U/ml penicillin, 50 g/ml streptomycin and 2 g/L sodium bicarbonate,
plus 10% FCS (Invitrogen Life Technologies). Cells were allowed to ad-
here for 3 h after which the plates were washed 2 times with RPMI 1640.
CD11b expression analysis on these adherent cells indicated similar per-
centages of CD11b myeloid cells in GPI-based treated/infected (97.3%)
versus mock-treated/infected (96.2%) mice. Cells were then stimulated
with sVSG (10 g/ml) or LPS (100 ng/ml) and incubated at 37°C, 5% CO2
for 24 h. Cell supernatants were collected and analyzed for cytokine
content.
LPS hypersensitivity
Based on previous data (30), T. brucei brucei infected GPI pre-exposed
mice were injected i.p. at 6 days p.i. with a range between 0.1 g and 50
g of LPS used for the determination of the LD50 LPS dose by peritoneal
administration. As such, the LD50 LPS dose was determined at 0.5 g/
mouse. Next, infected mock-treated mice were inoculated with 0.5 g of
LPS/mouse and mortality was recorded. Five mice were used per experi-
mental group.
Real-time quantitative PCR (RT-QPCR) analysis
RNA isolation was performed using RNAeasy kit (Qiagen). From each
sample 1 g of RNA was converted into cDNA using a Superscript II
reverse transcription reagent kit (Roche Molecular Systems). RT-QPCR
was performed on an iCycler apparatus using iQ SYBR Green Supermix
(Bio-Rad). PCR conditions were as described (31). Primers used were:
TNF-F: 5-CCTTCACAGAGCAATGACTC-3, TNF-R: 5-GTCTAC
TCCCAGGTTCTCTTC-3; IL-12 p40-F: 5-GAAAGACCCTGACCAT
CACT-3, IL-12 p40-R: 5-CCTTCTCTGCAGACAGAGAC-3; IL-
6-F: 5-GTCTTCTGGAGTACCATAGC-3, IL-6-R: 5-GTCAGATA
CCTGACAACAGG-3; IL10-F: 5-ACTCAATACACACTGCAGG
TG-3, IL10-R: 5-GGACTTTAAGGGTTACTTGG-3, Sepp1-F: 5-TT
CTGCAGGCATCCAGATTG-3, Sepp1-R: 5-CACAAGACGGCC
ACATCTGT-3, F13a1-F: 5-CCAGGAATTAAGCAAGACATC-3,
F13a1-R: 5-TGCCCTTACTTTCTAGTTCTC-3. Psap-F: 5-GCCATT
GTCATAGCACAGAG-3, Psap-R: 5-CTTCACTCATGAGGTGAAC
AG-3, Mrc-1-R: 5-GCAAATGGAGCCGTCTGTGC-3, Mrc-1-F: 5-
CTCGTGGATCTCCGTGACAC-3. Gene expression was normalized
against ribosomal protein s12 (31).
RBC clearance assay
Livers from T. brucei brucei-infected treated mice were isolated on day
8 p.i., cut into pieces, and incubated in RPMI 1640/0.01% collagenase
(Boehringer-Mannheim) for 1 h. After RBC lysis, cells were washed 3
times in complete RPMI 1640 and cultured at 5  105/ml in a 96-well
culture plate (Nunc). Following 3 h of adherence, cells were washed 3
times with complete RPMI 1640, and fresh medium was added. The ad-
herent cells from each group of mice were tested in FACS for CD11b
expression (GPI-based treated/infected 92.6.0% vs 94.8% for mock-treat-
ed/infected). Next, RBC from an infected mouse (day 4 p.i., RBCi) were
cocultured with adherent liver cells (AdLC) in a 10-fold excess ratio. After
24 h at 37°C, 5% CO2, the remaining amount of RBC was determined in
each well. The remaining RBC were obtained by aspirating the culture
medium and washing the adherent cells with 200 l fresh medium. Both
fractions were pooled and the RBC amount was determined by microscopy
counting using a hematocytometer. In an alternative experimental setup,
the AdLC were cultured with a monolayer of RBCi and then visually
inspected by microscopy. In a control experiment, the setup was repeated
using RBC isolated from noninfected mice.
Liver fractionation
Liver nonparenchymal cells were isolated as follows. Animals were eu-
thanized (CO2) and livers were perfused through the portal vein with 10 ml
of 100 U/ml collagenase type III (Worthington Biochemical) in HBSS.
Then, the liver was minced and incubated in 10 ml of 100 U/ml collagenase
III (20 min, 37°C). The resulting cell suspension was passed through a 100
m nylon mesh filter and then centrifuged (300  g, 10 min, 4°C). After
erythrocyte lysis, the pellet was resuspended in 10 ml of HBSS supple-
mented with 2 mM EDTA and 10% FCS and overlayed on 10 ml of Lym-
phoprep (Lucron Bioproducts). After centrifugation (430  g, 30 min,
17°C), the layer of low-density cells at the interface containing nonparen-
chymal cells was harvested.
MACS sorting
CD11b cells were isolated from the nonparenchymal cells of the liver by
positive CD11b selection on magnetic separation columns according to the
manufacturer’s protocol (Miltenyi Biotec) with a purity ranging from 85 to
95%. Cells were counted and used for further analysis by FACS or used for
RT-QPCR analysis (Trizol pellets of 3  106 cells, stored at 80°C).
Flow cytometry
MACS sorted liver cells from control, GPI-based treated and mock-treated
C57BL/6 mice before and at day 8–10 after T. brucei infection, were
further tested for purity via FACS. Briefly, starting from a stock solution of
5  106 cells/ml, 100 l was used for labeling. The cells were incubated
for 20 min at 4°C with Fc blocking Ab (2.4G2, BD Biosciences) to block
nonspecific binding and further surface stained with FITC conjugated rat
anti-CD11b (MAC-1) Ab (BD Pharmingen) or FITC conjugated matching
control Ab. The cells were washed twice with PBS before analyzing them
on FACSCanto II (BD Biosciences), using FACSDiva software (BD
Biosciences).
Statistical analysis
The GraphPad Prizm software was used for statistical analyses (Student’s
t test). Values of p  0.05 are considered statistically significant.
Results
GPI-based treatment reduces T. brucei brucei-elicited clinical
disease manifestations during infection
Clinical manifestation of African trypanosome infections is
marked by the occurrence of severe pathology, involving severe
weight loss, reduced locomotor activity, serum acidosis and ane-
mia. However, the most prominent feature of pathology is anemia,
the major cause of death of infected cattle (32). Studies in malaria
and other infectious diseases have shown that TNF plays a crucial
role in anemia development (33–35). This pathological symptom
was linked to the TNF-inducing capacity of parasite-released GPI
molecules (15). Important to mention is that trypanotolerance is
comprised of two parameters, 1) the capacity to limit parasite
growth and 2) the capacity to reduce anemia development that
occurs independent of parasite control (32). Hence, here the influ-
ence of GPI-based treatment on the induction of clinical disease
severity was analyzed in T. brucei brucei infected mice.
Starting from purified mfVSG of AnTat1.1 trypanosomes, the
GPI moiety was isolated. Conventional immunization with this
GPI in complete freund’s adjuvant (CFA), followed by boosting
with GPI in incomplete freund’s adjuvant failed to induce anti-GPI
Abs (data not shown) and did not affect the induction of anemia in
T. brucei brucei AnTat1.1 infected mice (Table I). Hence, alter-
native GPI immunization procedures were evaluated by 1) incor-
porating the GPI moiety into liposomes to increase its delivery and
retention, and 2) administrating 8-mercaptoguanosine (8-MG), a
biological response modifier that triggers T cell independent B cell
activation, including Ab isotype class switch to IgG (28, 36, 37),
to improve the immunogenicity of the GPI at the B cell level. The
adopted intraperitoneal (i.p.) immunization schedule included
treatment with 8-MG 2 h before administration of GPI liposomes,
repeated twice at 3 wk intervals, and was referred to as “GPI-
based” treatment (Fig. 1). Control groups included GPI liposome
treatment without 8-MG priming (GPI liposome) and empty-lipo-
some treatment with 8-MG (“mock”-treated) or without 8-MG
priming (Liposome).
Two weeks after the second GPI treatment, sera were evaluated
for the presence of anti-GPI Abs. Only GPI-based treated mice
developed low yet detectable levels of anti-mfVSG and anti-GPI
IgG Abs (Fig. 1, a and b, respectively).
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Three weeks after the second GPI-based treatment, mice were
challenged with T. brucei brucei AnTat1.1 and parasitemia, ane-
mia and survival were monitored. As shown in Fig. 2a (one rep-
resentative of eight individual experiments), there was no signif-
icant difference in initial parasite development (first waves of
parasitemia) between GPI-based treated and mock-treated infected
C57BL/6 mice. Regarding anemia development, Fig. 2, b and c
(one representative of eight individual experiments, summarized in
Table I) clearly show that the GPI-based treatment resulted in a
significant reduction in anemia as compared with mock-treated
mice. Hereby it should be emphasized that treatment with 8-MG
alone or pretreatment with GPI in the absence of 8-MG had no
effect on the anemia development (Table I). In addition GPI-based
treatment significantly prolonged the survival of infected mice as
compared with mock-treated/infected mice (Fig. 2, d and e,
respectively).
As mentioned above, in addition to anemia, experimental try-
panosome infections elicit other clinical disease symptoms (30,
38). Fig. 2f shows that while mock-treated mice exhibit serum
acidosis during the chronic anemic stage of infection, GPI-based
treated mice are rescued from this disease complication. Further-
more, trypanosome infections have been reported to result in se-
vere liver pathology (38), that can be monitored by measuring the
levels of serum AST. Indeed, as shown in Fig. 2g, the levels of
AST increase dramatically during the chronic stage of infection
and GPI-based treatment reduces AST levels to normal levels. Fi-
nally, T. brucei brucei infections were also documented to result in
severe weight loss and impairment of locomotor activity (30). Here
again GPI-based treatment significantly reduced these pathological
features (Fig. 2, h and i), and as such alleviates infection-associ-
ated morbidity throughout the chronic stage of infection.
Efficacy of the GPI-based treatment strategy in other models of
African trypanosomiasis
To evaluate the general applicability of the GPI-based treatment in
conferring protection against trypanosomiasis-associated immuno-
pathology, similar experiments were performed in different (mu-
rine) models of trypanosomiasis. Because T. congolense represents
a major cause of cattle trypanosomiasis, the protective effect of the
FIGURE 1. Overview of the GPI-based treatment setup and determina-
tion of the anti-GPI-specific Ab induction. Mice were injected i.p. with
8-MG 2 h before GPI liposome or mock liposome administration, and
boosted the same way 3 wk later. Serum Ab titers were measured in ELISA
on a solid-phase coating of mfVSG (a) or GPI (b). Serial serum dilutions
of GPI liposome-vaccinated mice (f) are plotted together with serial serum
dilutions of mock-vaccinated mice (). Results are presented as mean of
five individual serum samples  SD.
Table I. Overview of evaluated GPI and mock treatments in different mouse strainsa
Mouse Strain Treatment No. of Expts. No. of Mice/Expt. %RBC Reduction (day 18 p.i.) p Valueb
C57B1/6 CFA/ICFA 2 8 55.0 3.4
CFA/ICFA/GPI 2 8 56.0 2.9 0.5
C57B1/6 Mock 8 32 55.2 3.0
GPI-based 8 32 34.4 8.4 0.001
C57B1/6 Lipo 2 10 54.7 2.5
Lipo/GPI 2 10 51.7 1.5 0.1
C57B1/6 8 32 60.3 3.5
8-MG 8 32 57.8 2.6 0.1
C57B1/6 Mock 2 6 50.3 2.4
B cell/ GPI-based 2 6 31.1 2.3 0.05
C3H/N Mock 1 5 35.4 3.3
GPI-based 1 5 18.1 2.9 0.05
C3H Mock 1 7 28.3 2.3
TLR2/4/ GPI-based 1 7 12.1 2.1 0.05
C3H Mock 1 5 33.3 4.2
TLR4/ GPI-based 1 5 19.8 3.2 0.05
C57B1/6 Mock 2 8 40.0 1.7
CD1d/ GPI-based 2 8 37.9 2.5 0.5
a %RBC reduction values are calculated relative to naïve non-infected animals. Results are represented as mean values  SD.
b p values of results obtained in GPI-treated mice are calculated as compared to mock-treated mice.
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T. congolense GPI-based treatment was evaluated in infections
with the well documented (39) Tc13 T. congolense parasites. To
this end protection experiments in T. congolense infected C57BL/6
mice were conducted with T. congolense derived GPI. As shown in
Fig. 3a, the T. congolense GPI-based treatment reduced drastically
the level of anemia and caused a significant prolongation of the
mean survival time (MS: 155  12 days for GPI-based treated vs
126  5 days for mock-treated, p value: 0.014). A similar
FIGURE 2. GPI-based treatment confers protection
during T. brucei brucei infection. Parasitemia levels of
GPI-based treated (f) and mock-treated (Œ) mice (a).
Alterations in RBC counts (b) and survival times (d) of
GPI-based treated/infected C57BL/6 mice in the pres-
ence (f) or absence () of 8-MG are shown. Control
data include: alterations in RBC counts (c) and survival
times of mock-treated/infected mice (e) in the presence
(Œ) or absence (‚) of 8-MG. Results are presented as
mean % values of 10 individual mice  SD compared
with preinfection data. Alterations in serum pH (f) and
AST levels (g) as well as changes in total body mass (h)
and locomotor activity (i) were recorded for GPI-based
treated (black bars) and mock-treated (white bars) T.
brucei brucei-infected C57BL/6 mice, as well as non-
treated/infected mice (gray bars). Three mice per exper-
imental group were used, and the results are expressed
as means  SD.
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treatment was tested for another unrelated trypanosome species
namely T. evansi (ITMAS 110297, code KETRI 2480) and here
also a T. evansi GPI-based treatment impaired the development of
anemia and significantly prolonged the lifespan of T. evansi in-
fected mice (Fig. 3b) (MS: 48 5 days for GPI-based treated vs 22
5 days for mock-treated, p value: 0.001). Finally, also in a tsetse fly
transmitted trypanosome infection (AnTAR1) GPI-based treatment
protected mice against the development of anemia and resulted in a
significant prolongation in survival time (Fig. 3c) (MS: 33  3 days
for GPI-based treated vs 24 3 days for mock-treated, p value: 0.02).
Collectively these results show that pretreatment with the VSG-
derived GPI moiety alleviates the development of anemia in dif-
ferent experimental models of African trypanosomiasis.
The T. brucei brucei GPI-based treatment reduces
macrophage-mediated RBC destruction
As extravascular RBC destruction and liver macrophage-mediated
phagocytosis of RBCs have both been proposed as mechanisms
underlying anemia (40), RBC clearance was analyzed in an adher-
ent liver cell coculture system. As shown in Fig. 4a, when RBC
isolated from T. brucei brucei infected mice (RBCi) were exposed
to the adherent liver cell fraction isolated from infected mice at day
8 of infection, i.e., at the time point whereupon anemia appears in
vivo, they were efficiently cleared by adherent liver cells from
mock-treated/infected mice. In contrast, adherent liver cells from
GPI-based treated/infected mice had significantly reduced RBCi
clearance activity. In an alternative experimental setup, the ob-
served differences in RBC clearance activity were visualized by
light microscopy analysis of the integrity of an RBCi monolayer,
FIGURE 3. GPI-based treatment confers protection
in different trypanosome infection models. Alterations
in RBC counts and survival times of GPI-based treated
(f) or mock-treated () infected C57BL/6 mice are
shown. a, T. congolense GPI-based treatment and chal-
lenge; b, T. evansi KETRI 2480 GPI-based treatment
and challenge; c, AnTat1.1 GPI-based treatment fol-
lowed by tsetse-transmitted T. brucei AnTAR1 chal-
lenge. Results are presented as mean % values of five
individual mice  SD compared with preinfection data.
FIGURE 4. RBC clearance by AdLC of T. brucei brucei infected
C57BL/6 mice. a, RBC clearance by AdLC isolated from GPI-based
treated or mock-treated mice, before (white bars) or during infection (black
bars) with T. brucei brucei (day 8). Liver cells were incubated overnight
with RBC isolated from T. brucei brucei infected mice (RBCi) in a ratio of
1:10. RBC clearance was expressed as mean % clearance ( SD) of three
independent experiments compared with the initial RBC number. In an
alternative experimental setup, a RBCi monolayer was cultured overnight
on AdLC from mock-treated/infected mice (b), GPI-based treated/infected
mice (c), or noninfected mice (d). RBCi clearance was visualized as plague
formation under a light microscope.
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after 24 h incubation in the presence of adherent liver cells. Here,
adherent cells from mock-treated and infected mice destroyed the
RBCi monolayer, resulting in clearance plagues throughout all mi-
croscopy fields analyzed (Fig. 4b). In contrast, the number of
plagues caused by adherent liver cells from GPI-based treated/
infected mice was clearly reduced (Fig. 4c). Incubation of adherent
liver cells from noninfected mice with an RBCi monolayer did not
result in plague formation (Fig. 4d).
GPI-based treatment alleviates anemia in a B cell independent
manner
To assess whether the alleviation of anemia development by the
GPI-based treatment is Ab dependent, B cell deficient C57BL/6
mice were treated as described above. According to the results (Table
I) B cell deficient mice also develop anemia, indicating that Abs them-
selves play no significant role in anemia development. Furthermore
FIGURE 5. Modulation of T. brucei brucei infec-
tion-induced inflammation after GPI-based treatment. a,
TNF secretion by adherent peritoneal cells from GPI-
based treated (black bars) or mock-treated (white bars)
T. brucei brucei infected C57BL/6 (left panel) and
TLR4/ (right panel) mice restimulated in vitro at day
10 p.i. with sVSG or LPS. TNF secretion by adherent
peritoneal cells from naive C57BL/6 mice is shown in
gray bars. Five mice were used per experimental group.
b, Survival of GPI-based treated (f) or mock-treated T.
brucei brucei infected C57BL/6 mice () injected i.p.
at day 6 p.i. with 0.5 g of LPS, the LD50 dose for
infected GPI-based treated mice. Control mice injected
with the same LPS LD50 dose are represented by a gray
box. Five mice were used per experimental group, and
results are representative of one of two similar experi-
ments. c, TNF, IL-6, IL-12p40, and IL-10 gene expres-
sion levels were quantified by real-time PCR on adher-
ent peritoneal cells from GPI-based treated (black bars),
mock-treated (white bars) T. brucei brucei infected
C57BL/6 mice at day 10 p.i. Gene expression levels of
GPI-based treated and mock-treated noninfected
C57BL/6 mice are represented as gray bars. Fold induc-
tion gene expression was normalized using s12, relative
to noninfected mice. Five mice were used per experi-
mental group, and the results are expressed  SD.
Table II. Overview of plasma cytokine levels in GPI-based and mock-treated mice
Vaccination Scheme Postpeak (day 8) (pg/ml) Reduction/Increase (%) p Valueb 30 Days p.i. (pg/ml) Reduction/Increase (%) p Valueb
TNF No vacc. 270 20 50  12.5
Mock 229.2 15 15.1 42.3 21.6 15.4
GPI-based 63.1 9.8 73.7 0.0001 20.8 7.91 58.4 0.1
IL-6 No vacc. 1830 125 1560 125
Mock 1292 170 29.4 1107.6 22 29.0
GPI-based 375.6 50.6 79.5 0.001 370.23 50 76.3 0.005
IL-10 No vacc. 200 20 72  9.8
Mock 188.53 20 5.7 67.0 6.0 6.9
GPI-based 270.3 12 35 0.005 117  7.69 62.5 0.0001
a For all cytokines measured, 5 individual mice were used. Results are represented as mean values SD. Non-infected animals do not have detectable levels of any cytokine tested.
b p values are calculated as compared to mock-treated mice.
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GPI-based treatment alleviates anemia in B cell deficient mice.
Hence, although anti-GPI Abs were raised by this treatment, the effect
of GPI-based treatment on anemia is Ab-independent, indicating that
most likely cellular immune components are involved.
GPI-based treatment reduces T. brucei brucei-elicited type I
inflammation mediated by macrophages
Although it is well accepted that African trypanosome infections
results in macrophage activation, the status of macrophage activa-
tion however may influence the outcome of the disease. Indeed, the
sequential activation of classically activated macrophages (caM)
in a type I cytokine environment at the beginning of infection and
important to control the infection, followed by activation of alter-
natively activated macrophages (aaM) in a type II cytokine en-
vironment during the late/chronic stage of infection results in the
increased resistance against T. brucei brucei infections (41). How-
ever, persistence of a type I cytokine environment by caM during
chronic phase of infection may lead to pathology. This could be
attributed to the enhanced macrophage activation resulting in an
enhanced erythrophagocytosis (destruction of RBC) and finally
leading to anemia development.
To assess the influence of GPI-based treatment on the
inflammatory/anti-inflammatory cytokine balance of T. brucei bru-
cei infected mice serum levels of TNF, IL-6 and IL-10 were an-
alyzed on day 8 (early) and 30 (late) of infection. As shown in
Table II, GPI-based treatment reduced the circulating levels of the
inflammatory cytokine TNF during both the early and chronic late
stages of infection, as compared with mock-treated mice. The
same tendency was observed for serum levels of IL-6. In contrast,
GPI-based treatment significantly increased serum levels of the
anti-inflammatory cytokine IL-10, during both the early and late
stages of infection. These results suggest that the GPI-based treat-
ment tempers infection-elicited inflammatory type I response pos-
sibly by interfering with macrophage activation.
FIGURE 6. GPI-based treatment
modulates the macrophage activation
state during T. brucei infection. a,
RT-QPCR gene expression levels of
MACS purified CD11b liver cells
derived from GPI-based treated
(black box) and mock-treated (white
box) infected C57BL/6 mice. Gene
expression levels of IL-10 (top left)
and TNF (bottom left) for CD11b
cells derived from C57BL/6 mice. b,
Cytokine levels of IL-10 (top right)
and TNF (bottom right) from MACS
purified CD11b liver cells derived
from GPI-based treated (black box)
and mock-treated (white box) in-
fected C57BL/6 mice. c, RT-QPCR
gene expression levels of MACS pu-
rified CD11b cells from GPI-based
treated (black box) and mock-treated
(white box) noninfected and infected
C57BL/6 mice. Genes tested were
Sepp1 (top left), F13a1 (upper right),
Psap (lower left) and Mrc-1 (lower
right). Fold induction gene expres-
sion was normalized using s12, rela-
tive to noninfected mice. Dashed
lines represent gene expression lev-
els or cytokine levels of naive mice.
Five mice were used per experimen-
tal group, and the results are ex-
pressed  SD.
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To analyze the effect of the GPI-based treatment on infection-
associated TNF-secretion by macrophages, adherent peritoneal
cells, isolated at day 10 p.i., were stimulated in vitro with either
sVSG or LPS. As shown in Fig. 5a (left panel), GPI-based treat-
ment induced a significant down-regulation of TNF secretion by
sVSG or LPS-pulsed adherent peritoneal cells suggesting that this
treatment desensitizes the responsiveness of infection-associated
macrophages toward inflammatory components. This macrophage
desensitization was not attributed to the contamination of the GPI
liposome preparation with LPS, because both in TLR4/ as well
as TLR2/4/ mice this GPI-based treatment followed by a T.
brucei brucei challenge resulted in a significant impairment of ane-
mia development (Table I). Furthermore, in vitro restimulation of
adherent peritoneal cells from TLR4/ mice at day 10 p.i. with
sVSG confirmed that the macrophage desensitization by GPI-
based treatment did not rely on potential LPS contamination (Fig.
5a, right panel). Another connotation of this observation is that the
desensitization by the GPI-based treatment does not involve a
TLR4 signaling pathway. To test whether this state of desensiti-
zation was of any in vivo relevance, LPS-induced mortality, a
read-out for trypanosome elicited macrophage activation in vivo
(30), was compared in GPI-based treated and mock-treated in-
fected mice. According to Fig. 5b GPI-based treated mice exhib-
ited a LD50 LPS-dose of 0.5 g, when injected i.p. at day 6 of T.
brucei brucei infection. In contrast, in mock-treated infected mice
this LPS-dose caused 100% mortality within 24 h after injection.
Together these data show that GPI-based treatment resulted in a
desensitization of macrophages toward sVSG and LPS during in-
fection, in vitro as well as in vivo.
To further analyze the effect of GPI-based treatment on infection-
associated macrophage activation, mRNA levels of inflammatory cy-
tokines (TNF, IL-6, IL-12p40) and the anti-inflammatory cytokine
IL-10 were analyzed in different adherent peritoneal cell populations
collected at day 10 of infection. As shown in Fig. 5c, adherent peri-
toneal cells from GPI-based treated/infected mice showed a re-
duced TNF, IL-6, IL-12p40 expression and a clear up-regulation of
IL-10 expression as compared with mock-treated/infected mice. In
this context, it is important to mention that the GPI-based treat-
ment or mock-treatment itself did not induce any significant alter-
ation in the expression of the genes tested in the absence of a
trypanosome challenge (Fig. 5c).
GPI-based treatment modulates the macrophage activation state
during T. brucei infection
Given that 1) the liver is the major organ of parasite clearance and
RBC-destruction, 2) liver injury is a very important pathological
complication during infection (42), and 3) GPI-based treated/in-
fected mice exhibit reduced anemia and liver damage (AST lev-
els), the macrophage activation state in this organ was investi-
gated. First we evaluated gene-expression and protein secretion of
liver-derived CD11b cells to confirm the cytokine profiles ob-
served in the adherent peritoneal cell populations (see Fig. 5). As
shown in Fig. 6, a and b, the GPI-based treatment results in de-
creased TNF and increased IL-10 production, both at gene-expres-
sion and protein secretion level. Next, purified liver-derived
CD11b cells were thoroughly analyzed in terms of gene expres-
sion of aaM markers (43). RT-QPCR analysis revealed higher
expression levels of genes associated with protection against oxi-
dative burst (Sepp (44)), tissue repair and wound healing (F13a1,
(45)), prevention of apoptosis (Psap, (46)) and down-regulation of
inflammation (Mrc1, (47) in GPI-based treated/infected mice as
compared with mock-treated/infected mice (Fig. 6c). Collectively,
these data indicate that GPI-based treatment triggers the develop-
ment of aaM.
The protective effect of the GPI-based treatment during
T. brucei brucei infection involves a CD1d-mediated pathway
It is well documented that glycolipids, including GPI’s from T.
brucei, can be presented in the context of CD1d, expressed on
APCs, resulting in the activation of CD1d-restricted T cells (27,
48, 49). Therefore, the possible involvement of the CD1d-medi-
ated pathways in the protective effects observed in GPI-based
treated/infected animals was envisaged and evaluated using
CD1d/ mice. As shown in Table I, the protective effect of the
GPI-based treatment, with respect to alleviation of anemia, was
abrogated (%RBC reduction at day 18 p.i. in GPI-based treated
37.9  2.5% and mock-treated 40.0  1.7%), confirming a pos-
sible involvement of the CD1d-pathway.
Discussion
During parasitic infections, we and others have shown that patho-
gen derived GPI is involved in TNF induction (10–12), hereby
playing a major role in induction of pathology and the clinical
manifestation of infection (50, 51). Early on after the discovery of
the structure of the GPI from trypanosome VSG, GPI anchors were
described in plasmodium (52, 53) and identified as the malaria-
toxin capable of inducing TNF production when added to macro-
phage cultures (54). Detailed analysis of the functional structure of
plasmodium GPI, in the context of macrophage activation, lead to
the identification of two distinct structural elements, the carbohy-
drate and lipid moieties respectively (20). Although the glycan
core was found to activate protein tyrosine kinase, the diacylglyc-
erol moiety was proposed to function as a second messenger for
protein kinase C activation (20). Together, these GPI-triggered sig-
nal pathways induce the secretion of proinflammatory cytokines
including TNF as well as IL-1 and IL-6 (55, 56). Hereby the in-
duction of TNF by plasmodium GPI in macrophages required rec-
ognition of the distal fourth mannose residue of the glycan core
(57). Accordingly, interfering with this recognition can inhibit the
macrophage-activating potential of the GPI moiety. In this vein a
successful vaccination strategy was developed by Schofield et al.
(19) based on a synthetic carbohydrate moiety that mimics the
plasmodium GPI core. Indeed, conventional immunizations using
CFA with this synthetic component resulted in the production of
neutralizing anti-GPI Abs and those Abs were shown to be able to
neutralize the TNF induction by macrophages exposed to plasmo-
dium extracts. Furthermore in challenge experiments, this vacci-
nation conferred partial protection against malarial pathogenesis.
Based on the documented role of the GPI moiety of VSG in
trypanosomiasis-associated pathology (12), an anti-trypanosome
GPI intervention strategy was envisaged to protect against sleeping
sickness. In contrast to plasmodium GPI, trypanosome GPI lacks a
fourth -mannose but has a galactose modification linked to the
first mannose which is essential for TNF induction (12). However,
the presence of an inducible endogenous trypanosome phospho-
lipase C (PLC) enzyme hampers an intervention approach based
solely on the carbohydrate core. Indeed, upon external stress, try-
panosomes cleave most of their VSG by using their PLC, releasing
sVSG that harbors the GPI carbohydrate moiety and leaving the
GPI dimeristoylglycerol (DMG) lipid anchor in the membrane
(58). Hence, while inhibition of plasmodium GPI could be
achieved through the generation of neutralizing Abs recognizing
the carbohydrate core, such approach will not affect or neutralize
the DMG lipid-moiety that accounts for induction of LPS-hyper-
sensitivity during trypanosome infections (12). Therefore in this
study uncleaved VSG-derived GPI encompassing the glycan and
lipid moieties, obtained through the chemical inhibition of the try-
panosome PLC was used. To increase the retention, delivery and
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immunogenicity of the GPI molecule a new intervention strategy
based on liposome encapsulation combined with the immuno-
modulator 8-mercaptoguanosine was developed. This GPI-based
treatment resulted in a significant protection against host clinical
manifestations of T. brucei-induced pathology like anemia, acido-
sis, serum AST levels, weight loss and locomotor activity, without
influencing initial parasite development.
In addition, this GPI-based treatment was found to be successful
in preventing the development of anemia in other more relevant
infectious trypanosome systems, like T. congolense and T. evansi.
Moreover even in a more natural system, using tsetse fly trans-
mission, the GPI-based treatment resulted in significant protection
against anemia development.
Surprisingly, although anti-GPI Abs were raised by the GPI-
based treatment strategy, the efficacy of GPI-based treatment at the
level of anemia did not rely on the humoral immune responses as
GPI-based treated, infected B cell deficient mice also exhibited
similar protection as compared with GPI pre-exposed and infected
wild-type C57BL/6 mice. Therefore, the protective effects ob-
served in our GPI-based treatment intervention strategy might rely
on a different mechanism than that one proposed by Schofield et al.
(19) in the malaria GPI vaccination model, where Abs were sug-
gested to be crucial for the protective effects. This could be due to
a difference in the Ag used. Indeed, while in the case of malaria a
well defined, synthetic carbohydrate moiety was used, in the
present studies the whole GPI was administered including its mac-
rophage modulating components.
Hence, we propose that the success of the GPI-based treatment
intervention strategy relies on an attenuation of parasite-elicited
type I inflammation, in particular at the level of macrophage ac-
tivation. Collectively our results are highly supportive for this as-
sumption. First, GPI-based treatment shifted the balance of (pro)-
inflammatory cytokines TNF and IL-6 toward IL-10 in the serum
during infection. Second, GPI-based treatment influenced the mac-
rophage activation state elicited during the early phase of African
trypanosome infections. At this stage macrophages are primed by
IFN-, and further triggered by trypanosome released sVSG/
mfVSG (12, 59) and possibly by LPS. Indeed, LPS is detectable in
the serum of trypanosome infected animals, presumably due to
ongoing gut-inflammation and bacterial leakage (60). Together,
this leads toward a hyperactive classical activation state of mac-
rophages (caM or M1), prone to produce massive amounts of
TNF (12, 61). Such caM were found herein to be desensitized by
the GPI-based treatment as evidenced by their impaired capacity to
produce TNF upon triggering with sVSG or LPS. Moreover, GPI-
based treated T. brucei brucei infected mice were found to be more
resistant to LPS-mediated lethality. This desensitization, or as
some may refer to as tolerance, was not due to a potential LPS
contamination of the GPI liposome preparation because GPI-based
treated, T. brucei brucei infected TLR4/ as well as TLR2/4/
mice were found to be protected against anemia development (see
Table I).
Furthermore, at the mRNA level, macrophages from GPI-based
treated/infected animals exhibited a reduced TNF, IL-6 and IL-
12p40 gene expression and increased IL-10 gene expression as
compared with mock-treated/infected animals. This type of mac-
rophages has been documented by Mantovani et al. (62) to reflect
M2 macrophages. In addition, the expression levels of putative
aaM marker genes (Ghassabeh et al. (43), Sepp, F13a1, Mrc1 and
Psap) were found to be up-regulated in CD11b cells from GPI-
based treated/infected mice as compared with mock-treated/in-
fected mice. Collectively, our data therefore suggest that the
GPI-based treatment fuels the generation of alternatively acti-
vated anti-inflammatory macrophages (aaM/M2) (62) during
African trypanosome infection. However, we do not rule out a
possible involvement of other cellular players in the observed in-
duction of TNF, IL-6 and IL-12p40 during the course of infection,
because dendritic cells as well as adipocytes were reported to be
potent producers of proinflammatory cytokines in response to TLR
ligands (63, 64).
Though the mechanisms underlying this macrophage repro-
gramming are so far not determined, at least one possibility is
worthwhile to consider. As demonstrated by Coller et al. (59) the
timing of macrophage exposure to the GPI moiety of VSG may
determine the inflammatory response to trypanosome infections.
Indeed while macrophage activation by IFN-, mimicking early
priming during trypanosome infections, favors the expression of
TNF, IL-1 and IL-12p40 in response to GIPs, i.e., the GPI anchor
substituent associated with sVSG (sVSG/GIP), treatment with
sVSG/GIP before IFN- stimulation resulted in a marked reduc-
tion of IFN--induced responses such as iNOS. The inhibitory
activity of GPI-related molecules on macrophage activation was
also reported for Leishmania major, where a glycoinositol-phos-
pholipid was found to inhibit the synthesis of IFN--dependant
NO production (65). According to our results, macrophage repro-
gramming through GPI pre-exposure, impacts on macrophage- and
TNF-mediated clinical disease symptoms such as anemia, serum
acidosis, liver damage, and weight loss. As severe anemia is con-
sidered the most important cause of death in natural T. brucei
brucei as well as T. congolense infections, this parameter of pa-
thology was analyzed in more detail. Because erythrophagocytosis
was documented to contribute to extensive extra-vascular destruc-
tion of RBCi during African trypanosomiasis (66), the protective
effect of GPI pre-exposure on infection-associated anemia might
again reflect a modulation of the macrophage activation state. In-
deed, while adherent liver cells from infected mice destroy RBCi
in vitro, GPI-based treatment greatly reduced this activity. There-
fore, switching from a caM state during early state of infection to
a more aaM state during the course of infection, via the GPI-
based treatment, could play a role in reduced development of
anemia.
In conclusion, the results presented herein show that GPI-based
treatment alleviates infection-associated pathology during African
trypanosomiasis, resulting in an increased lifespan of the infected
host. This intervention strategy reduced the inflammatory immune
response during infection, resulting in a desensitization and alter-
native activation of macrophages. These aaM could play a car-
dinal role in the GPI-based treatment, as these cells produce high
levels of IL-10 and express genes potentially involved in anti-
inflammation and tissue repair. Finally, the CD1d signaling path-
way was found to be crucial for the beneficial effects of the GPI-
based treatment, suggesting a link between CD1d signaling and
development of aaM.
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